Indian pharmaceutical major Zydus Cadila has applied to the DCGI for emergency use authorization (EUA) for ZyCoV-D, a plasmid DNA vaccine against COVID-19. 

This vaccine, when injected, produces the spike protein of the SARS-CoV-2 virus and triggers an immune response which is mediated by the cellular and humoral components of the immune system. Dr Sharvil Patel, MD, Cadila Healthcare Ltd (Zydus Cadila Group), said that the vaccine has shown its safety and efficacy profile, and once approved, it will benefit adults as well as adolescents aged 12-18 years. This vaccine has also been tested in the 12-18 years age group in India. Nearly 1,000 participants were recruited in the trial and the vaccine was found to be safe and well-tolerated, like in adults… (ET Healthworld – TNN, July 2, 2021)